Format

Send to

Choose Destination
Clin Lab Med. 2014 Mar;34(1):87-97, vi-vii. doi: 10.1016/j.cll.2013.11.009. Epub 2014 Jan 14.

Soluble ST2 and galectin-3 in heart failure.

Author information

1
Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
2
Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: jjanuzzi@partners.org.

Abstract

Circulating biomarkers that directly reflect disease progression, hemodynamics, and ventricular remodeling at a molecular level are critical to risk stratification in heart failure (HF), affording unique insights into pathophysiology not fully captured by traditional risk markers. Despite the wealth of data confirming the importance of natriuretic peptides in HF diagnosis and prognosis, residual clinical risk in HF suggests that additional biomarkers complementary to natriuretic peptides may be useful. In this article, the current literature addressing the role of these biomarkers in the clinical diagnosis and risk stratification in HF is summarized.

KEYWORDS:

Biomarkers; Cardiac markers; Laboratory medicine

PMID:
24507789
DOI:
10.1016/j.cll.2013.11.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center